ContraFect Appoints Clinical Development Leader, Cara Cassino, M.D., as Chief Medical Officer September 16, 2015
ContraFect Corporation Announces Poster Presentation at the ICAAC/ICC 2015 Meeting for CF-301 for the Treatment of Staph Aureus Infections, Including MRSA September 9, 2015
FDA Grants Fast Track Designation to ContraFect's CF-301, the First of Its Lysins, Currently in Development for the Treatment of Staph Aureus Infections, Including MRSA August 17, 2015
ContraFect Corporation Announces Issuance of Key Patent Covering Novel Lysin Technology July 17, 2015
